Stock Events

Stock Events

Kymera Therapeutics 

$117.39
24
+$0.11+0.09% Friday 20:00
+$0.00+0%Friday 20:10After hours

Statistics

Day High
117.5
Day Low
117.26
52W High
130.05
52W Low
42.22
Volume
15,243
Avg. Volume
-
Mkt Cap
9.76B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.24
-1.03
-0.83
-0.62
Expected EPS
-1.239699
Actual EPS
N/A

Financials

-794.04%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
39.21MRevenue
-311.35MNet Income

Analyst Ratings

135.33Average Price Target
The highest estimate is 170.00.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KYMR. It's not an investment recommendation.
Tesla
10
TSLA
Apple
9
AAPL
Amazon
9
AMZN
NVIDIA
9
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, including a focus on protein degradation, which competes with Kymera's targeted protein degradation platform.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company that has been expanding its research in targeted protein degradation, directly competing with Kymera's core research focus.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has been investing in the development of novel therapeutics, including those in the protein degradation space, making it a competitor to Kymera.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a broad focus on innovative therapeutics, including research into protein degradation mechanisms, positioning it as a competitor.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has shown interest in targeted protein degradation, competing with Kymera in the quest to develop novel treatments for diseases.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has initiatives in novel therapeutic areas, including protein degradation, which aligns with Kymera's research interests.
Merck
MRK
Mkt Cap366B
Merck is engaged in drug discovery and development, including areas that overlap with Kymera's focus on protein degradation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diverse research portfolio that includes work on protein degradation, making it a competitor in the space.
Rogers
ROG
Mkt Cap2.24B
Roche, through its Genentech arm, is involved in research that competes with Kymera, including the development of treatments based on protein degradation.

About

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Show more...
CEO
Nello Mainolfi
Employees
273
Country
United States
ISIN
US5015751044

Listings

BOATS
BOATS
KYMR.BOATS
XNAS
US
KYMR

0 Comments

Share your thoughts

FAQ

What is Kymera Therapeutics stock price today?▼
The current price of KYMR is $117.39 USD — it has increased by +0.09% in the past 24 hours. Watch Kymera Therapeutics stock price performance more closely on the chart.
What is Kymera Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Kymera Therapeutics stocks are traded under the ticker KYMR.
Is Kymera Therapeutics stock price growing?▼
KYMR stock has fallen by -0.64% compared to the previous week, the month change is a +11.29% rise, over the last year Kymera Therapeutics has showed a +169.8% increase.
What is Kymera Therapeutics market cap?▼
Today Kymera Therapeutics has the market capitalization of 9.76B
When is the next Kymera Therapeutics earnings date?▼
Kymera Therapeutics is going to release the next earnings report on October 29, 2026.
What were Kymera Therapeutics earnings last quarter?▼
KYMR earnings for the last quarter are -0.62 USD per share, whereas the estimation was -0.71 USD resulting in a +12.99% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kymera Therapeutics revenue for the last year?▼
Kymera Therapeutics revenue for the last year amounts to 39.21M USD.
What is Kymera Therapeutics net income for the last year?▼
KYMR net income for the last year is -311.35M USD.
How many employees does Kymera Therapeutics have?▼
As of September 05, 2026, the company has 273 employees.
In which sector is Kymera Therapeutics located?▼
Kymera Therapeutics operates in the Health & Wellness sector.
When did Kymera Therapeutics complete a stock split?▼
Kymera Therapeutics has not had any recent stock splits.
Where is Kymera Therapeutics headquartered?▼
Kymera Therapeutics is headquartered in WATERTOWN, United States.